Inflammatory Markers Response to Citrulline Supplementation in Patients with Non-alcoholic Fatty Liver Disease: a Randomized, Double Blind, Placebo-controlled, Clinical Trial

Overview

Journal BMC Res Notes

Publisher Biomed Central

Specialties Biology
General Medicine

Date 2019 Feb 16

PMID 30767788

Citations 10

Authors

Zahra Darabi

Mina Darand

Zahra Yari

Mehdi Hedayati

Amirhosein Faghihi

Shahram Agah

Azita Hekmatdoost

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to investigate the effects of citrulline (Cit) supplementation on inflammatory markers and liver histopathology in patients with non-alcoholic fatty liver disease (NAFLD). In this clinical trial, fifty NAFLD patients were assigned to receive 2 g/day Cit or placebo for 3 months.

Results: At the end of study, serum high sensitive C-reactive protein (hs-CRP) and activity of nuclear factor kappa B (NF-κB) were reduced in Cit group significantly more than placebo group (P-value = 0.02 and < 0.01 respectively). Serum concentrations of tumor necrosis factor-α (TNF-α) was reduced in Cit group significantly more than placebo after adjusting for levels of baseline (P-value < 0.001). Moreover, Cit supplementation decreased serum alanine aminotransferase (ALT) and hepatic steatosis significantly (P = 0.04). Anthropometric measurements and hepatic enzymes did not change significantly in any group (P ≥ 0.05). In conclusion, our results showed that 12 weeks supplementation with 2 g/day Cit improved inflammatory markers in patients with NAFLD. Further studies with longer period of supplementation and different dosages of Cit are needed to be able to conclude. Trial registration IRCT201703194010N18 on 2017-10-13.

Citing Articles

Impact of L-Citrulline Supplementation and HIIT on Lipid Profile, Arterial Stiffness, and Fat Mass in Obese Adolescents with Metabolic-Dysfunction-Associated Fatty Liver Disease: A Randomized Clinical Trial.

Rodriguez-Carrillo A, Espinoza-Vargas M, Vargas-Ortiz K, Ibarra-Reynoso L, Olvera-Juarez M, Gomez-Ojeda A Nutrients. 2025; 17(3).

PMID: 39940261 PMC: 11820369. DOI: 10.3390/nu17030402.

Immunomodulatory and biological properties of helminth-derived small molecules: Potential applications in diagnostics and therapeutics.

Yeshi K, Ruscher R, Loukas A, Wangchuk P Front Parasitol. 2025; 1():984152.

PMID: 39816468 PMC: 11731824. DOI: 10.3389/fpara.2022.984152.

Citrulline and ADI-PEG20 reduce inflammation in a juvenile porcine model of acute endotoxemia.

Vonderohe C, Stoll B, Didelija I, Nguyen T, Mohammad M, Jones-Hall Y Front Immunol. 2024; 15:1400574.

PMID: 39176089 PMC: 11338849. DOI: 10.3389/fimmu.2024.1400574.

Dose-response effect of L-citrulline on skeletal muscle damage after acute eccentric exercise: an study in mice.

Ghozali D, Doewes M, Soetrisno S, Indarto D, Ilyas M PeerJ. 2023; 11:e16684.

PMID: 38130917 PMC: 10734431. DOI: 10.7717/peerj.16684.

Exploring the Impact of Nutrition on Non-Alcoholic Fatty Liver Disease Management: Unveiling the Roles of Various Foods, Food Components, and Compounds.

Kosmalski M, Frankowski R, Deska K, Rozycka-Kosmalska M, Pietras T Nutrients. 2023; 15(13).

PMID: 37447164 PMC: 10343927. DOI: 10.3390/nu15132838.

References

Ainsworth B, Haskell W, Whitt M, Irwin M, Swartz A, Strath S . Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32(9 Suppl):S498-504. DOI: 10.1097/00005768-200009001-00009. View

Guo F, Cavener D . The GCN2 eIF2alpha kinase regulates fatty-acid homeostasis in the liver during deprivation of an essential amino acid. Cell Metab. 2007; 5(2):103-14. DOI: 10.1016/j.cmet.2007.01.001. View

Cynober L, Moinard C, De Bandt J . The 2009 ESPEN Sir David Cuthbertson. Citrulline: a new major signaling molecule or just another player in the pharmaconutrition game?. Clin Nutr. 2010; 29(5):545-51. DOI: 10.1016/j.clnu.2010.07.006. View

El-Kirsh A, El-Wahab H, Abd-Ellah Sayed H . The effect of L-arginine or L-citrulline supplementation on biochemical parameters and the vascular aortic wall in high-fat and high-cholesterol-fed rats. Cell Biochem Funct. 2011; 29(5):414-28. DOI: 10.1002/cbf.1766. View

Malekzadeh R, Poustchi H . Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon. 2011; 11(3):157-8. PMC: 3206683. View

Abenavoli L, Beaugrand M . Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol. 2012; 11(2):172-8. View

Locatelli I, Sutti S, Vacchiano M, Bozzola C, Albano E . NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. Clin Sci (Lond). 2012; 124(4):279-87. DOI: 10.1042/CS20120289. View

Ghaemi A, Taleban F, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z . How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?. Hepat Mon. 2013; 13(12):e15227. PMC: 3867211. DOI: 10.5812/hepatmon.15227. View

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A . Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99(3):535-42. DOI: 10.3945/ajcn.113.068890. View

10.

Breuillard C, Bonhomme S, Couderc R, Cynober L, De Bandt J . In vitro anti-inflammatory effects of citrulline on peritoneal macrophages in Zucker diabetic fatty rats. Br J Nutr. 2014; 113(1):120-4. DOI: 10.1017/S0007114514002086. View

11.

Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A . Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015; 7(2):204-12. PMC: 4342602. DOI: 10.4254/wjh.v7.i2.204. View

12.

Jegatheesan P, Beutheu S, Ventura G, Sarfati G, Nubret E, Kapel N . Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin Nutr. 2015; 35(1):175-182. DOI: 10.1016/j.clnu.2015.01.021. View

13.

Hillenbrand A, Kiebler B, Schwab C, Scheja L, Xu P, Henne-Bruns D . Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. BMC Res Notes. 2015; 8:290. PMC: 4490690. DOI: 10.1186/s13104-015-1224-7. View

14.

Jegatheesan P, Beutheu S, Ventura G, Nubret E, Sarfati G, Bergheim I . Citrulline and Nonessential Amino Acids Prevent Fructose-Induced Nonalcoholic Fatty Liver Disease in Rats. J Nutr. 2015; 145(10):2273-9. DOI: 10.3945/jn.115.218982. View

15.

Perriotte-Olson C, Adi N, Manickam D, Westwood R, Desouza C, Natarajan G . Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity. Obesity (Silver Spring). 2015; 24(1):148-56. PMC: 6699510. DOI: 10.1002/oby.21348. View

16.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

17.

Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A . Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 2016; 67(4):461-9. DOI: 10.3109/09637486.2016.1161011. View

18.

Cai B, Luo Y, Wang S, Wei W, Zhang X, Huang W . Does Citrulline Have Protective Effects on Liver Injury in Septic Rats?. Biomed Res Int. 2016; 2016:1469590. PMC: 4853932. DOI: 10.1155/2016/1469590. View

19.

Jegatheesan P, Beutheu S, Freese K, Waligora-Dupriet A, Nubret E, Butel M . Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats. Br J Nutr. 2016; 116(2):191-203. DOI: 10.1017/S0007114516001793. View

20.

Hekmatdoost A, Shamsipour A, Meibodi M, Gheibizadeh N, Eslamparast T, Poustchi H . Adherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of Nonalcoholic Fatty Liver Disease. Int J Food Sci Nutr. 2016; 67(8):1024-9. DOI: 10.1080/09637486.2016.1210101. View